Improving radiotherapy for children's brain tumors
Enhanced radiotherapy for pediatric glioma via synthetic lethal vulnerabilities
This study is looking for better ways to help kids with a tough brain cancer called diffuse midline gliomas by using special techniques to find new treatments that can work alongside radiation therapy, with the hope of improving their chances of recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10996979 on NIH RePORTER |
What this research studies
This research focuses on enhancing the effectiveness of radiotherapy for pediatric patients with diffuse midline gliomas (DMG), a type of brain cancer that is difficult to treat. The team is investigating specific vulnerabilities in these tumors using advanced techniques like CRISPR to identify potential drug targets. By combining radiation therapy with new drugs that affect DNA repair mechanisms, the goal is to improve survival rates for children suffering from this aggressive cancer. This approach aims to make radiotherapy more effective and potentially reduce the recurrence of tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years diagnosed with diffuse midline gliomas.
Not a fit: Patients with other types of brain tumors or those outside the specified age range may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates for children with diffuse midline gliomas.
How similar studies have performed: Other research has shown promise in using synthetic lethality approaches in cancer treatment, indicating potential for success in this novel application.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Chowdhury, Dipanjan — Dana-Farber Cancer Inst
- Study coordinator: Chowdhury, Dipanjan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.